bioMérieux – Second-Quarter 2020 Business Performance Preannoucement

09 July, 2020

Marcy l'Étoile (France), July 9, 2020 – In light of the withdrawal of its annual objectives, bioMérieux, a world leader in the field of in vitro diagnostics, today announced preliminary quarterly information about its business activity ending June 30, 2020.

  • Organic growth of 15.7% at constant exchange rates and scope of consolidation over the first half of 2020:
    • €1,476 million in sales
    • Up 15.8% as reported
  • Sustained positive momentum of molecular biology product lines
  • As expected, adverse impact of the global health crisis on microbiology, immunoassay and industrial applications product lines

About bioMérieux

Pioneering Diagnostics

A world leader in the field of in vitro diagnostics for over 50 years, bioMérieux is present in more than 43 countries and serves more than 160 countries with the support of a large network of distributors. In 2018, revenues reached €2.4 billion, with over 90% of international sales.

bioMérieux provides diagnostic solutions (systems, reagents, software, and services) which determine the source of disease and contamination to improve patient health and ensure consumer safety. Its products are mainly used for diagnosing infectious diseases. They are also used for detecting microorganisms in agri-food, pharmaceutical and cosmetic products.

bioMérieux is listed on the Euronext Paris stock market
Symbol: BIM – ISIN Code: FR0013280286
Reuters: BIOX.PA/Bloomberg: BIM.FP


Corporate website: Investor website:


Investor Relations

Sylvain Morgeau
Tel.: +33 (0)4 78 87 22 37

Media Relations

Aurore Sergeant
Tel.: +33 (0)4 78 87 20 53

Image Sept
Laurence Heilbronn
Tel.: +33 (0)1 53 70 74 64

Claire Doligez
Tel.: +33 (0)1 53 70 74 48

Download the Full Press Release:

Pioneering Diagnostics